Compass Therapeutics

Antibody Therapies

Also Clin1b colorectal cancer, Clin1b ovarian cancer; CTX-471 2 efforts Clin0/Clin1b oncology, CTX-8371 Clin0 oncology; undisclosed RD autoimmune condition

Compass Therapeutics focuses on high-throughput screening of antibody therapeutics for cancer and autoimmune disorders using common light-chain platforms. Compass utilizes common light chains both in vivo and in vitro to produce diverse panels that are screened using next generation mammalian display filters with a turnaround time of 8 weeks from antigen to optimized monoclonal antibodies produced in cell culture. Compass’s StitchMabs technology also allows them to produce highly specific bi- and mutli-specific biologics. Bispecific biologics are screened in large matrices to increase the likelihood of discovering novel synergistic combinations. The Compass pipeline is focused on therapies aimed at either activating or releasing immune suppression of T cells, NK cells, and macrophages.